Payment overview · 2025
General Payments
$235.44
18 reported records · 5 companies
Healthcare provider profile · identity verified
Matthew David Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOPKINSVILLE, KY · NPI 1790929248
Verified facts
What the public records show
CMS Open Payments records show Matthew David Smith, M.D. received $235.44 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 58.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.18 | 58.7% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.12 | 13.2% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $28.17 | 12.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.59 | 10.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.38 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $235.44 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.18 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 510 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 72 |
| Gabapentin | Gabapentin | 282 | 73 |
| Alprazolam | Alprazolam | 259 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 243 | 49 |
| Lisinopril | Lisinopril | 239 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 44 |
| Omeprazole | Omeprazole | 168 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 166 | 26 |
| Furosemide | Furosemide | 159 | 37 |
| Losartan Potassium | Losartan Potassium | 136 | 32 |
| Meloxicam | Meloxicam | 134 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 31 |
| Montelukast Sodium | Montelukast Sodium | 122 | 32 |
| Metformin Hcl | Metformin Hcl | 120 | 28 |
| Lorazepam | Lorazepam | 116 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 28 |
| Simvastatin | Simvastatin | 105 | 28 |
| Potassium Chloride | Potassium Chloride | 103 | 19 |
| Trazodone Hcl | Trazodone Hcl | 101 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 19 |
| Eliquis | Apixaban | 94 | 16 |
| Tramadol Hcl | Tramadol Hcl | 93 | 20 |
| Carvedilol | Carvedilol | 92 | 19 |
| Famotidine | Famotidine | 84 | 23 |
| Valsartan | Valsartan | 82 | 17 |
| Azithromycin | Azithromycin | 77 | 68 |
| Clonazepam | Clonazepam | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 67 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 16 |
| Diazepam | Diazepam | 65 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 15 |
| Sertraline Hcl | Sertraline Hcl | 62 | 12 |
| Amoxicillin | Amoxicillin | 61 | 53 |
| Prednisone | Prednisone | 61 | 48 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 19 |
| Spironolactone | Spironolactone | 59 | 18 |
| Fluconazole | Fluconazole | 58 | 29 |
| Pregabalin | Pregabalin | 58 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 12 |
| Bupropion Xl | Bupropion Hcl | 55 | 13 |
| Ozempic | Semaglutide | 55 | suppressed |
| Carisoprodol | Carisoprodol | 51 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 51 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Allopurinol | Allopurinol | 49 | 15 |
| Ondansetron Odt | Ondansetron | 47 | 17 |
| Finasteride | Finasteride | 46 | 11 |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 37 |
| Meclizine Hcl | Meclizine Hcl | 40 | 20 |
| Temazepam | Temazepam | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 11 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Cefdinir | Cefdinir | 18 | 14 |
| Cephalexin | Cephalexin | 18 | 14 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Sucralfate | Sucralfate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Nucynta | Tapentadol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $235.44 · 18 records | ABBVIE INC. | CAPLYTA, Dexcom G6 Transmitter, ImmunoCAP, VRAYLAR, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error